Analyst Consensus ?
ConsensusBuy33 ratings
Bullish2678.8%
Neutral721.2%
Bearish00.0%
MetLife, Inc. · MET · FY2025 Q2 · Calendar Q3 2025
MetLife: Asia growth offsets underwriting and investment pressure
MetLife's growth initiatives and regional sales momentum support the longer-term strategy, but the near-term earnings picture remains balanced by underwriting pressure, lower variable investment income and commercial-mortgage risk.
Reported After market closeNYSEFinancial Services
$62.52B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.02
Consensus $2.15
EPS surprise
-6.0%
Reported versus consensus
Reported revenue
$17.34B
Consensus $18.53B
Revenue surprise
-6.4%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-2.8%
Event window
SPY move
-0.1%
Same window
Abnormal move
-2.7%
Stock minus SPY
Volume
1.8×
Versus trailing sessions
Subsequent drift
+7.7%
Up to 20 sessions
METSPY benchmark
Ask FN2 about MET FY2025 Q2
Transcript, numbers and history already loaded
Why did MET fall 2.8% after missing EPS estimates in FY2025 Q2?What changed in MET's guidance and outlook in FY2025 Q2?Give me the bull and bear case for MET after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the company continued to emphasize Asia and Latin America growth, strategic transactions and expense discipline, while adjusted earnings were down 16% year over year and underwriting and variable-investment-income pressure remained central concerns.
Guidance delta
Management's guidance sentiment was maintained; it expects improvement in Q3 and Q4 while continuing its New Frontier strategy.
Key takeaways
- Asia sales momentum and new FX annuity products remain important growth drivers.
- Underwriting pressure and lower variable investment income weighed on the quarter.
- Expense discipline remained a support, with the direct expense ratio at 11.7% versus a 12.1% target.
- PineBridge, Chariot Re, Workday and early AI initiatives extend the company's strategic agenda.
Management priorities
- Advance the PineBridge acquisition and expand investment-management capabilities.
- Scale Chariot Re and pursue additional risk-transfer transactions.
- Expand AI applications across claims, programming and call centers.
- Continue capital returns while funding growth initiatives and developing new products.
Follow MET with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$95.76Current
$68Low
$94.17Average
$145High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 7, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Oct 6, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 5, 2026 |
| Piper Sandler | Overweight | Neutral | Upgrade | Sep 22, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 24, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 19, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Aug 11, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 11, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 13, 2026 |
| Jefferies | Buy | Buy | Maintain | Jul 10, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 9, 2026 |
| B of A Securities | Buy | Buy | Maintain | Apr 14, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 23, 2024 |
| Argus Research | Buy | Buy | Maintain | May 22, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 9, 2024 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 4, 2023 |
| Raymond James | Perform | Market Perform | Maintain | Sep 22, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 22, 2022 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Aug 19, 2022 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 12, 2019 |
| Sandler O'Neill | Hold | Buy | Downgrade | Mar 19, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Jan 16, 2019 |
| B. Riley Securities | Neutral | Neutral | Maintain | Jul 16, 2018 |
| B. Riley FBR | Neutral | Neutral | Maintain | Jul 16, 2018 |
| Atlantic Equities | Overweight | Neutral | Upgrade | Mar 26, 2018 |
| Argus | Buy | Buy | Maintain | Nov 6, 2017 |
| FBR Capital | Neutral | Buy | Downgrade | Oct 10, 2017 |
| Macquarie | Outperform | Outperform | Maintain | Feb 4, 2016 |
| Keefe Bruyette & Woods | Outperform | Outperform | Maintain | Oct 12, 2015 |
| Sterne Agee | Buy | Buy | Maintain | Oct 13, 2014 |
| Drexel Hamilton | Buy | Buy | Maintain | Jul 7, 2014 |
| Janney Montgomery Scott | Buy | Neutral | Upgrade | Jan 3, 2014 |
| Janney Capital | Buy | Neutral | Upgrade | Jan 3, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $95.76. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Michael Ward | $110 | $96.88 | +14.9% | Oct 6, 2026 |
| Piper Sandler | Paul Newsome | $110 | $96.64 | +14.9% | Sep 22, 2026 |
| Morgan Stanley | Bob Huang | $111 | $95.75 | +15.9% | Aug 24, 2026 |
| Wells Fargo | Analyst unavailable | $109 | $96.73 | +13.8% | Aug 19, 2026 |
| Barclays | Analyst unavailable | $97 | $96.26 | +1.3% | Aug 6, 2026 |
| Atlantic Equities | Analyst unavailable | $103 | $92.44 | +7.6% | Jul 15, 2026 |
| Jefferies | Suneet Kamath | $103 | $91.15 | +7.6% | Jul 10, 2026 |
| UBS | Michael Ward | $105 | $90.27 | +9.6% | Jul 8, 2026 |
| Barclays | Alex Scott | $94 | $90.46 | -1.8% | Jul 7, 2026 |
| Morgan Stanley | Analyst unavailable | $103 | $90.93 | +7.6% | Jul 6, 2026 |
| Piper Sandler | Analyst unavailable | $90 | $88.03 | -6.0% | Jun 24, 2026 |
| Piper Sandler | Analyst unavailable | $86 | $84.06 | -10.2% | May 26, 2026 |
| Morgan Stanley | Bob Huang | $93 | $83.5 | -2.9% | May 21, 2026 |
| Wells Fargo | Analyst unavailable | $95 | $77.98 | -0.8% | May 12, 2026 |
| Mizuho Securities | Yaron Kinar | $95 | $78.82 | -0.8% | May 8, 2026 |
| Barclays | Alex Scott | $93 | $80.16 | -2.9% | May 7, 2026 |
| Mizuho Securities | Yaron Kinar | $93 | $74.63 | -2.9% | Apr 13, 2026 |
| Evercore ISI | Analyst unavailable | $96 | $74.65 | +0.3% | Apr 9, 2026 |
| UBS | Analyst unavailable | $102 | $74.65 | +6.5% | Apr 9, 2026 |
| Mizuho Securities | Analyst unavailable | $100 | $78.89 | +4.4% | Feb 12, 2026 |
| Evercore ISI | Thomas Gallagher | $95 | $77.92 | -0.8% | Feb 10, 2026 |
| UBS | Analyst unavailable | $98 | $78.01 | +2.3% | Feb 5, 2026 |
| Mizuho Securities | Analyst unavailable | $102 | $77.08 | +6.5% | Jan 14, 2026 |
| Wells Fargo | Elyse Greenspan | $97 | $78.32 | +1.3% | Jan 13, 2026 |
| UBS | Analyst unavailable | $94 | $79.79 | -1.8% | Jan 8, 2026 |
| Barclays | Analyst unavailable | $90 | $79.47 | -6.0% | Jan 8, 2026 |
| Evercore ISI | Analyst unavailable | $97 | $81.77 | +1.3% | Jan 6, 2026 |
| Mizuho Securities | Analyst unavailable | $101 | $82.62 | +5.5% | Dec 15, 2025 |
| Morgan Stanley | Analyst unavailable | $101 | $83.22 | +5.5% | Dec 15, 2025 |
| Barclays | Analyst unavailable | $98 | $82.75 | +2.3% | Oct 8, 2025 |
| Morgan Stanley | Bob Huang | $97 | $82.7 | +1.3% | Oct 7, 2025 |
| Piper Sandler | John Barnidge | $84 | $79.07 | -12.3% | Sep 19, 2025 |
| Wolfe Research | Tracy Benguigui | $95 | $80.46 | -0.8% | Sep 15, 2025 |
| Morgan Stanley | Bob Huang | $98 | $77.74 | +2.3% | Jul 14, 2025 |
| Piper Sandler | John Barnidge | $94 | $82.49 | -1.8% | Apr 2, 2025 |
| Morgan Stanley | Analyst unavailable | $109 | $86.18 | +13.8% | Feb 28, 2025 |
| Piper Sandler | John Barnidge | $92 | $81.78 | -3.9% | Oct 2, 2024 |
| Barclays | Alex Scott | $91 | $77.52 | -5.0% | Sep 4, 2024 |
| Bank of America Securities | Joshua Shanker | $96 | $76.85 | +0.3% | Aug 1, 2024 |
| Morgan Stanley | Bob Huang | $83 | $69.92 | -13.3% | Jul 10, 2024 |
| Argus Research | Kevin Heal | $80 | $73.15 | -16.5% | May 22, 2024 |
| Piper Sandler | John Barnidge | $82 | $70.94 | -14.4% | May 6, 2024 |
| CFRA | Catherine Seifert | $77 | $72.67 | -19.6% | Mar 13, 2024 |
| Goldman Sachs | Alex Scott | $80 | $68.92 | -16.5% | Jan 8, 2024 |
| Mizuho Securities | Brett Linzey | $145 | $63.79 | +51.4% | Sep 14, 2023 |
| Morgan Stanley | Analyst unavailable | $90 | $72.68 | -6.0% | Feb 2, 2023 |
| Morgan Stanley | Analyst unavailable | $88 | $71.35 | -8.1% | Jan 10, 2023 |
| Goldman Sachs | Analyst unavailable | $78 | $73.58 | -18.5% | Jan 9, 2023 |
| J.P. Morgan | Analyst unavailable | $80 | $73.58 | -16.5% | Jan 6, 2023 |
| Jefferies | Analyst unavailable | $82 | $73.61 | -14.4% | Dec 9, 2022 |
| Morgan Stanley | Analyst unavailable | $87 | $74.01 | -9.1% | Nov 17, 2022 |
| Credit Suisse | Analyst unavailable | $77 | $67.39 | -19.6% | Aug 22, 2022 |
| Morgan Stanley | Analyst unavailable | $83 | $67.25 | -13.3% | Aug 17, 2022 |
| Morgan Stanley | Analyst unavailable | $79 | $64.14 | -17.5% | Aug 4, 2022 |
| Barclays | Analyst unavailable | $75 | $57.79 | -21.7% | Jul 14, 2022 |
| Evercore ISI | Analyst unavailable | $80 | $61.4 | -16.5% | Jul 6, 2022 |
| Morgan Stanley | Analyst unavailable | $78 | $61.58 | -18.5% | Jul 6, 2022 |
| Wolfe Research | Charles Lederer | $74 | $61.75 | -22.7% | Jun 22, 2022 |
| Morgan Stanley | Analyst unavailable | $80 | $67.23 | -16.5% | May 5, 2022 |
| Evercore ISI | Thomas Gallagher | $75 | $64.18 | -21.7% | Jan 5, 2022 |
| Goldman Sachs | Alex Scott | $77 | $58.92 | -19.6% | Dec 2, 2021 |
| Credit Suisse | Andrew Kligerman | $68 | $63.12 | -29.0% | May 13, 2021 |
| Argus Research | Kevin Heal | $72 | $65.2 | -24.8% | May 7, 2021 |
Track every rating change on MET the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisions: the U.S., Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings. Its broad insurance offerings include life, dental, group short-term and long-term disability, individual disability, pet, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans. MetLife also supports employers with administrative services-only (ASO) arrangements. Furthermore, it provides sophisticated financial instruments such as general and separate account contracts, synthetic guaranteed interest contracts, and private floating rate funding agreements.…
Historical context
All MET earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| FDS FactSet Research Systems Inc. | FY2026 Q4 · Calendar Q3 2026 | +3.9% | +3.8% | FactSet reports record FY26 results as AI and MCP adoption accelerate |
| PUK Prudential plc | FY2026 Q2 · Calendar Q3 2026 | -40.9% | -0.5% | Prudential sustains growth and capital returns focus in H1 2026 |
| CM Canadian Imperial Bank of Commerce | FY2026 Q3 · Calendar Q3 2026 | +8.9% | -2.8% | CIBC Q3: Broad growth, resilient credit and expanded AI rollout |
| TD The Toronto-Dominion Bank | FY2026 Q3 · Calendar Q3 2026 | +13.8% | +1.4% | TD emphasizes growth investments alongside disciplined capital management |
| RY Royal Bank of Canada | FY2026 Q3 · Calendar Q3 2026 | +6.2% | -1.3% | RBC reports record Q3 earnings while investing for growth |
| AFRM Affirm Holdings, Inc. | FY2026 Q4 · Calendar Q3 2026 | +1230.3% | +0.3% | Affirm's most profitable quarter shifts focus to product execution |
Latest beats and misses
Who reports nextBeat on EPS
- LWFY2027 Q1 · October 6, 2026+27.8% EPS+7.5% move
- RPMFY2027 Q1 · October 6, 2026+1.5% EPS+3.2% move
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
Get the MET recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-07T16:00:43.710140+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-07T16:00:43.706805+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-07. For educational purposes only; not investment advice.